A few months ago, a CFO of a large health system told our team something that's stuck with me. They’d never had to think hard about drug spend, because "there's so much money that comes into the system that we’ve invested very little in the analytics of drug profitability at the margin."

He could tell you what a drug cost. He could not tell you, at the individual drug and dose level, whether the system was making or losing money on it. That gap, not a lack of data, but a lack of context, is the story of healthcare expense management today, and I think it's the next frontier CFOs need to conquer.

Revenue got smart. Expense didn't.

Many health system CFOs are investing resources into building out their revenue strategy: managed care contracting, denials management, underpayment recovery, payer performance analytics. It's producing results. Most systems now have real infrastructure, including the teams, tools, and context layer dedicated to protecting and growing the revenue line.

Expense management hasn't gone through the same evolution. It's still mostly treated as a control function: set a budget, track variance, find the outliers, cut what's over. That's necessary. 

It's also incomplete, because it treats every dollar in the expense ledger as if it exists in isolation from the revenue it helps produce.

That’s not how things work. And CFOs who don't correct for that are going to keep leaving margin on the table, or worse, cutting the wrong things.

The pharmacy problem

Here's the pattern we see constantly. A CFO pulls up the drug spend report and sees a specialty biologic costing the system an enormous amount per dose. The instinct is obvious: this is an insanely expensive drug, we should be steering away from it. But that instinct is only looking at half the P&L. The same drug, priced and billed correctly, with the right site-of-care and payer mix, can produce a strong positive margin.

Look at expense alone, and you might cut a profit center. Look at revenue alone and you could miss a cost problem hiding in plain sight. Look at both together—margin per unit, per drug, per encounter—and you get an informed decision that moves margin in the right direction.

We hear this same tension almost every week from finance and pharmacy teams who are only each seeing part of the picture. Which drugs are on 340B versus GPO pricing? Where does biosimilar substitution change the margin equation entirely? How are the "cost" and “revenue” lines being managed by two different departments that rarely talk?

One health system finance leader we work with described drug margin analysis as "the other mammoth of manual interventions.” Not because the data doesn't exist, but because nobody has stitched expense and revenue together at the level of granularity where the decision actually lives.

Pharmacy is just the clearest example. The same logic runs through supply chain, surgical implants, and service-line cost allocation. An expense line is never just an expense line. It's an input to margin.

Labor is the biggest version of this problem

Nowhere is the “expense vs. margin” tension bigger than labor, which is usually the single largest cost line on a health system's P&L, and the one most often managed as pure cost control.

But labor isn't a pure expense. More clinical FTEs, in the right place, can directly produce more revenue: more encounters, more RVUs, more surgical capacity. We've sat with finance teams building the exact tradeoff: "if we add 5% more positions, what's the corresponding revenue lift, and does it outpace the compensation increase?" That's a fundamentally different question than "how do we get labor expense down," and it's the question CFOs increasingly need an answer to.

The nuance matters here, and good finance teams already sense it intuitively, even if their tools don't support it well: overtime and premium labor is a different animal from strategic staffing investment. Bringing down avoidable overtime is straightforward cost control. Deciding whether to add a physician, an APP, or a nursing FTE is a margin investment decision that requires seeing the downstream revenue, not just the expense line. Collapsing those two into one "labor expense" bucket, the way most reporting still does, is why so many staffing conversations end up either reflexively defensive or reflexively austere.

The real gap: nobody owns "expense strategy"

Health systems are starting to build a muscle around revenue strategy, usually sitting with a CRO, a VP of managed care, or a revenue cycle leader who is measured on yield, not just collections. Almost none have an equivalent counterpart on the expense side. Cost containment sits in finance. Labor sits in HR and operations. Pharmacy margin sits with pharmacy. Supply chain sits with sourcing. Each function optimizes its own line item, and nobody is accountable for the thing that actually matters: the margin that results from expense and revenue moving together.

That's the gap we think the next generation of healthcare CFOs need to close, not by hiring more analysts to build more spreadsheets, but by building an actual expense strategy capability: a team, a mindset, and the underlying financial infrastructure to see cost and revenue in the same view, at the same level of granularity, continuously, instead of once a month after the P&L closes.

We hear this from finance leaders constantly, in different words. One CFO's team told us bluntly: "We're not used to worrying about expenses here. It's just been an open checkbook, and we can't continue that." Another described trying to align staffing decisions to actual revenue lift: "what dollars does that bring, what's the staffing model, and how does that net out?" Both are describing the same missing muscle. It's not a data problem. It's an accountability and visibility problem.

What this means in practice

This is why we built Translucent the way we did. We didn't want to build another expense-reduction dashboard, or another revenue-cycle point solution sitting next to it, unconnected. We built a single financial context layer spanning the physician enterprise, the hospital, revenue intelligence, and pharmacy, so that a service line's productivity, labor expense, payer performance, and drug margin all live in one place, with AI agents that trace root cause across all of it and hand finance and operating leaders a dollar figure, a location, and a recommended action, not just a variance to explain away.

Boards and CEOs have already accepted that the CFO role has become an enterprise-strategy seat, not a bookkeeping one. The next step is accepting that "cost control" and "revenue strategy" are not two separate disciplines to be led by two different teams with two different scorecards. They're one discipline, margin intelligence, and it requires the full picture, expense and revenue together, to actually move.

The health systems that build that capability first won't just save money. They'll make better decisions about where to invest, not just where to cut. That's the difference between a finance function that reacts to the P&L and one that shapes it.

‍